TBI-1301-A

TBI-1301-A is an investigational T-cell receptor (TCR) engineered T-cell therapy targeting the cancer-testis antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1). Developed by Takara Bio, the therapy involves the genetic modification of T lymphocytes to express a specific TCR that recognizes NY-ESO-1 peptides presented by HLA-A*02:01 or HLA-A*02:06. In the specific context of the jRCT2080223774 trial, TBI-1301-A utilizes donor-derived T cells (allogeneic) for patients with refractory adult T-cell leukemia/lymphoma (ATLL) who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy aims to induce a targeted anti-tumor immune response against NY-ESO-1-expressing leukemia cells, potentially enhancing the graft-versus-leukemia effect while minimizing the risk of graft-versus-host disease.

Other names

NY-ESO-1 TCR-transduced T lymphocytesNY-ESO1 TCR-transduced T lymphocytesNY-ESO 1 TCR-transduced T lymphocytesNY-ESO-1-specific TCR gene-transduced T lymphocytesNY-ESO1-specific TCR gene-transduced T lymphocytesNY-ESO 1-specific TCR gene-transduced T lymphocytesNY-ESO-1 TCR-TNY-ESO1 TCR-TNY-ESO 1 TCR-T